Ji Caica Consumer Medical: Growing up hormones and dental implants, who is the next?

One news that has no reason allows "Northeast Yao Mao" Changchun High -tech to fall into trouble.

On August 17, the Zhejiang Pharmaceutical Procurement Platform issued the "Notice on Following the Opinions of the Third Batch of Pharmaceutical Procurement Documents for the Public Medical Structure of Zhejiang Province". Unlike other collecting documents, the column of the "collection variety" of this document is empty.

But soon, a table was reported on the Internet. It involves the main variety of Changchun High -tech: growth hormone.

Source network

Prior to this, the Guangdong Alliance had a collection of growth hormones. At that time, Changchun High -tech shocked a cold sweat, and the stock price dropped a lot. Now Zhejiang also comes, the market is naturally worried: the national collection of hormones may not be far away.

On August 18, Changchun High -tech declined by 10%, of which the institution sold was nearly 400 million yuan. On August 19, Changchun High -tech stock price continued to decline. As of the close, Changchun High -tech declined by 4.21%.

Earlier this year, the attention of the pharmaceutical industry gradually deviated from innovative drugs and began to turn to consumer medical care. It was believed that the needs of medical beauty, increased, hair transplantation, oral and myopia treatment will erupt.

Now 8 months have passed, and consumer medical treatment has not ushered in the imagination, but it has ushered in collective collection.

Jiji "Sniper" Changchun High -tech

Due to the collapse of the stock price, Changchun High -tech is not the first time.

In January of this year, the Guangdong Pharmaceutical Exchange Center released the "Pharmaceutical Purchase Purchasing Documents such as Binocrootic acid and other drugs in Guangdong", which contains growth hormones.

The Guangdong Alliance has nearly ten provinces including Jiangxi and Shanxi, and the area covers half of China. Jiji will reduce the price, and the operating performance may not be guaranteed. Three trading days after the collection documents, Changchun's high -tech stock price continued to fall, and the market value evaporated exceeding 26 billion yuan.

Growth hormones have always been the main profit for Changchun High -tech. In 2021, the net profit of Golden Pharmaceutical, which operates growth hormones under Changchun High -tech, was 4.463 billion yuan, while the total net profit of Changchun High -tech was 3.757 billion yuan. This means that Jin Sai Pharmaceutical also subsidizes Changchun High -tech.

Therefore, Changchun High -tech is most afraid of the "top beam column" to be cut off. Therefore, during the declaration, Changchun High -tech only reported non -core powder needles, and the core water needle of the profit did not apply for collection at all. In the total revenue of Changchun High -tech growth hormones, the powder needle accounts for only 10%.

In the end, the selected varieties selected by the Guangdong Alliance were all pink needles, and there was no water needle. This gives some confidence in the market: the core disk of collecting hormones is difficult to shake the hormone.

However, soon, the Qinghai Pharmaceutical Purchase Center released news that the price of long -term water needles (54IU /9.0 mg /1.0ml) of Changchun High -tech core products decreased from the original 5600 yuan to 3500 yuan, a decrease of 37.5% Essence

The price of the most basic powder needle is inevitable that some patients will choose cheap products. Changchun High -tech itself also responded that the price reduction is conducive to long -term water needles occupying market share as soon as possible, and the company is fully promoting long -term growth hormones.

It is not a good thing to cover the cloudy clouds on his head. Although many institutions have participated in Changchun High -tech investor relations in the first half of the year and conducted detailed analysis of the status of growth hormone participation in the collection, the first reaction of the institutions was still: run.

In this regard, Changchun High -tech response is: this is just a solicitation opinion, and the company does not receive a formal notice.

Rectify consumer medical care or become the next trend

Whenever he encounters a collection of collection, the situation of Changchun High -tech represents the external environment of consumer medical care.

Unlike conventional medical care, consumer medical care is not a necessary service for cure, but the purpose of serving patients to improve the quality of personal life. Such services are usually not carried out in public hospitals and basically need to be at their own expense.

Because of this, consumer medical companies are basically not affected by collective mining, and the gross profit margin is high, and it has long been in a high valuation stage for a long time. According to Changchun High -tech annual reports, its gross profit margin of the pharmaceutical industry reached more than 90%. The same "tooth" Tongmei medical treatment belongs to consumer medical care, "Eye" Alier Ophthalmology, and Medical Aesthetic represents Aimei, and was once regarded as the Nuggets on the Golden Circuit.

However, since this year, the valuation of such companies has been rapidly reshaping. One of the reasons is that the foundation of consumer medical care -the consumption power of residents has undergone tremendous changes.

According to the Chinese Government Network, in the first half of this year, the average per capita disposable income of residents across the country increased by 4.7%, which was far lower than 12.6%of the same period last year. It shows that residents' income growth is weak and the willingness to control consumption is enhanced.

Tuyuan China Government Network

The daily needs such as clothing, food, housing, and transportation still continue to continue. At this time, the policy has to come out and gradually squeeze out some non -rigid industries.

Dental implants are the first field to be stared at. Because of the large demand and high price, the public complains more. Earlier this year, the State Council made it clear that it would promote dental implants as soon as possible.

Sure enough, on August 18, the National Medical Insurance Administration officially launched a special rectification operation for dental implants and treatment fees. This action directly aimed at the core business of dental listed companies such as Tongmei Medical.

In the future, whether the more beautiful industries such as medical beauty and hair transplantation will be included in the collection, it is really hard to say. After the price of drugs, the charges for the use of medicines and diagnosis and treatment services may become the focus of rectification in the next stage.

#Consumer Medical ## National Collection#

- END -